article thumbnail

New FDA guidance on addressing misinformation under White House review

Agency IQ

BY LAURA DIANGELO, MPH A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA). Fill out the form to read the full article.

FDA 59
article thumbnail

Analysis Chemical Thank You Senate hearing on hazardous substance listing for PFAS finds common ground, but disagreements on implementation tactics

Agency IQ

The testimony of witnesses and the Senators themselves largely agreed on the designation, but diverged on questions of liability exemptions. How the agency plans to regulate PFAS via CERCLA In late 2021, the EPA published the PFAS Strategic Roadmap , which laid out the planned PFAS strategy for the agency between 2021 and 2024.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Investment will enable pHion to progress its lead program into the clinic 

Drug Discovery World

s National Security and Investment Act, testimony to invoX’s continued willingness to build trust and work closely with regulators. This investment has received all required regulatory approvals, including clearance from the regulatory agency in charge of enforcing the U.K.’s

Vaccine 130
article thumbnail

Analysis Chemical Thank You Freedhoff testifies in front of Senate EPW over TSCA implementation

Agency IQ

SHELLEY MOORE CAPITO (R-WV) opened the testimony. Carper noted that the issues with how the EPA has implemented TSCA has led to “grievances” from both the chemical industry and environmental advocates, as the flow of chemicals to market and regulation of harmful chemicals has slowed. Opening Sen. TOM CARPER (D-DE) and Sen.

article thumbnail

Bogus ‘Cure’ Claims Have U.S. Consumers Snapping Up CBD Products

The Pharma Data

A random sample of 376 posts labeled testimonials found that 90% cited using CBD to treat diagnosable medical conditions. Nearly two-thirds of the testimonials discussed its use for treating mental or emotional problems. Nearly two-thirds of the testimonials discussed its use for treating mental or emotional problems.

article thumbnail

Article FDA Thank You In unanimous decision, Supreme Court solves FDA’s ‘standing’ issue

Agency IQ

They were not subject to any direct regulation by the FDA related to mifepristone. Plaintiffs lack Article III standing to challenge FDA’s actions regarding the regulation of mifepristone,” the court wrote. While other parties may still sue the FDA over its regulation of mifepristone, the Court’s decision is important for the FDA.

FDA 40
article thumbnail

Article FDA Thank You New FDA guidance on addressing misinformation under White House review

Agency IQ

New FDA guidance on addressing misinformation under White House review A new question-and-answer draft guidance document focused on “addressing misinformation” about regulated life sciences products is currently under administrative review at the White House’s Office of Information and Regulatory Affairs (OIRA).

FDA 40